| Randomized withdrawal study | Extension study | ||
---|---|---|---|---|
 | Open-label period | Double-blind period |  |  |
Vital signs, mean (SD) | Milnacipran n = 116 | Placebo n = 6 | Milnacipran n = 14 | Milnacipran n = 57 |
Systolic BP, mm Hg | Â | Â | Â | Â |
Baselinea | 113.3 (9.7) | 117.3 (7.9) | 115.0 (7.7) | 112.5 (8.7) |
Change | 4.1 (8.9) | −1.2 (6.8) | −1.4 (10.9) | 2.5 (10.7) |
Diastolic BP, mm Hg | Â | Â | Â | Â |
Baselinea | 69.5 (7.8) | 76.3 (9.3) | 70.8 (10.4) | 68.1 (8.7) |
Change | 5.2 (8.6) | −7.0 (8.3) | −0.1 (9.9) | 4.2 (8.8) |
Heart rate, bpm | Â | Â | Â | Â |
Baselinea | 81.0 (11.1) | 100.5 (17.9) | 87.1 (17.5) | 81.6 (10.8) |
Change | 10.0 (14.4) | −6.8 (16.0) | 0.1 (18.6) | 4.3 (11.1) |
Body weight, kg | Â | Â | Â | Â |
Baselinea | 69.4 (17.6) | 71.9 (20.7) | 64.7 (14.2) | 68.9 (18.1) |
Change | −0.8 (2.0) | 1.9 (1.7) | −0.1 (1.9) | −0.5 (3.9) |